Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
16.76
-0.05 (-0.30%)
At close: Apr 28, 2026, 4:00 PM EDT
16.99
+0.23 (1.37%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Theravance Biopharma Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Theravance Biopharma stock have an average target of 18.4, with a low estimate of 15 and a high estimate of 24. The average target predicts an increase of 9.79% from the current stock price of 16.76.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Theravance Biopharma stock from 6 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Buy | 0 | 1 | 1 | 1 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B. Riley Securities | B. Riley Securities | Hold Maintains $14 → $17 | Hold | Maintains | $14 → $17 | +1.43% | Apr 7, 2026 |
| TD Cowen | TD Cowen | Hold Maintains $13 → $15 | Hold | Maintains | $13 → $15 | -10.50% | Mar 23, 2026 |
| BTIG | BTIG | Strong Buy Reiterates $21 | Strong Buy | Reiterates | $21 | +25.30% | Mar 20, 2026 |
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Mar 5, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $27 → $15 | Strong Buy | Maintains | $27 → $15 | -10.50% | Mar 4, 2026 |
Financial Forecast
Revenue This Year
116.56M
from 107.46M
Increased by 8.46%
Revenue Next Year
86.70M
from 116.56M
Decreased by -25.62%
EPS This Year
1.92
from 2.06
Decreased by -6.91%
EPS Next Year
0.43
from 1.92
Decreased by -77.34%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 191.6M | 94.1M | ||||||
| Avg | 116.6M | 86.7M | ||||||
| Low | 75.9M | 77.2M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 78.3% | -19.3% | ||||||
| Avg | 8.5% | -25.6% | ||||||
| Low | -29.4% | -33.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 2.18 | 0.74 | |||||
| Avg | 1.92 | 0.43 | |||||
| Low | 1.48 | 0.15 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 6.0% | -61.6% | |||||
| Avg | -6.9% | -77.3% | |||||
| Low | -28.2% | -92.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.